WGS GeneDx Holdings Corp

  1. Stocks
  2. Healthcare
  3. NASDAQ: WGS

Price (delayed)

$56.335

Market cap

$1.67B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.66

Enterprise value

$1.75B

?
Relative Growth: Rel. Growth: 32
Relative Strength: Rel. Strength: 5
Relative Valuation: Rel. Valuation: 15
Relative Profitability: Rel. Profitability: 23

Sema4 is a patient-centered health intelligence company dedicated to advancing healthcare through data-driven insights. Sema4 is transforming healthcare by applying AI and machine learning to multidimensional, longitudinal clinical and genomic ...

Highlights
The gross profit is up by 43% year-on-year and by 3.3% since the previous quarter
WGS's revenue is up by 34% year-on-year and by 3.5% since the previous quarter
WGS's quick ratio is up by 25% since the previous quarter but it is down by 4.1% year-on-year
The net income has shrunk by 102% YoY
GeneDx Holdings's EPS has shrunk by 89% YoY
Sector: Healthcare
Industry: Health Information Services
Website: http://sema4.com
Peers: NEOG NTRA MYGN

Key stats

What are the main financial stats of WGS

WGS stock price

How has the GeneDx Holdings stock price performed over time
Intraday
6.25%
1 week
12.33%
1 month
-17.07%
1 year
-22.18%
YTD
-56.69%
QTD
-12.28%

Financial performance

How have GeneDx Holdings's revenue and profit performed over time
Revenue
$442.68M
Gross profit
$307.91M
Operating income
-$66M
Net income
-$77.81M
Gross margin
69.6%
Net margin
-17.6%
The net income has shrunk by 102% YoY
WGS's net margin has dropped by 50% year-on-year
The gross profit is up by 43% year-on-year and by 3.3% since the previous quarter
WGS's revenue is up by 34% year-on-year and by 3.5% since the previous quarter

Price vs fundamentals

How does WGS's price correlate with its fundamentals

Growth

What is GeneDx Holdings's growth rate over time

Valuation

What is GeneDx Holdings stock price valuation
P/E
N/A
P/B
6.49
P/S
3.73
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
3.95
GeneDx Holdings's EPS has shrunk by 89% YoY
The stock's P/B is 42% more than its 5-year quarterly average of 4.3 but 38% less than its last 4 quarters average of 9.9
The company's equity fell by 18% QoQ
The stock's P/S is 61% below its last 4 quarters average of 8.9 and 12% below its 5-year quarterly average of 4.0
WGS's revenue is up by 34% year-on-year and by 3.5% since the previous quarter

Efficiency

How efficient is GeneDx Holdings business performance
The ROIC has plunged by 82% YoY
The ROA has dropped by 69% year-on-year
The ROE has plunged by 61% YoY
GeneDx Holdings's return on sales has shrunk by 58% YoY

Dividends

What is WGS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for WGS.

Financial health

How did GeneDx Holdings financials performed over time
WGS's total assets is 101% greater than its total liabilities
The total liabilities has grown by 33% YoY and by 17% from the previous quarter
The current ratio has increased by 26% since the previous quarter but it has declined by 4.9% year-on-year
WGS's debt is 34% smaller than its equity
The debt to equity has surged by 89% since the previous quarter and by 47% year-on-year
WGS's debt has surged by 55% since the previous quarter and by 46% year-on-year

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.